308 related articles for article (PubMed ID: 15908753)
1. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
Dautzenberg FM; Neysari S
Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
[TBL] [Abstract][Full Text] [Related]
2. Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions.
Akerberg H; Fällmar H; Sjödin P; Boukharta L; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Regul Pept; 2010 Aug; 163(1-3):120-9. PubMed ID: 20471432
[TBL] [Abstract][Full Text] [Related]
3. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.
Fällmar H; Åkerberg H; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Neuropeptides; 2011 Aug; 45(4):293-300. PubMed ID: 21696823
[TBL] [Abstract][Full Text] [Related]
4. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
[TBL] [Abstract][Full Text] [Related]
5. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
8. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
Silva AP; Carvalho AP; Carvalho CM; Malva JO
Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
[TBL] [Abstract][Full Text] [Related]
11. Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon.
Goumain M; Voisin T; Lorinet AM; Laburthe M
Biochem Biophys Res Commun; 1998 Jun; 247(1):52-6. PubMed ID: 9636652
[TBL] [Abstract][Full Text] [Related]
12. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors.
El Bahh B; Balosso S; Hamilton T; Herzog H; Beck-Sickinger AG; Sperk G; Gehlert DR; Vezzani A; Colmers WF
Eur J Neurosci; 2005 Sep; 22(6):1417-30. PubMed ID: 16190896
[TBL] [Abstract][Full Text] [Related]
13. Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors.
Widdowson PS; Buckingham R; Williams G
Brain Res; 1997 Dec; 778(1):242-50. PubMed ID: 9462897
[TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of rabbit neuropeptide Y receptor subtypes.
Umeda T; Kanatani A; Iwaasa H
Peptides; 2009 Aug; 30(8):1441-7. PubMed ID: 19481128
[TBL] [Abstract][Full Text] [Related]
15. Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues.
Hyland NP; Sjöberg F; Tough IR; Herzog H; Cox HM
Br J Pharmacol; 2003 Jun; 139(4):863-71. PubMed ID: 12813010
[TBL] [Abstract][Full Text] [Related]
16. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
[TBL] [Abstract][Full Text] [Related]
17. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.
Abounader R; Elhusseiny A; Cohen Z; Olivier A; Stanimirovic D; Quirion R; Hamel E
J Cereb Blood Flow Metab; 1999 Feb; 19(2):155-63. PubMed ID: 10027771
[TBL] [Abstract][Full Text] [Related]
18. Expression cloning of a human brain neuropeptide Y Y2 receptor.
Gehlert DR; Beavers LS; Johnson D; Gackenheimer SL; Schober DA; Gadski RA
Mol Pharmacol; 1996 Feb; 49(2):224-8. PubMed ID: 8632753
[TBL] [Abstract][Full Text] [Related]
19. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
Gehlert DR; Shaw JL
Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y regulates recurrent mossy fiber synaptic transmission less effectively in mice than in rats: Correlation with Y2 receptor plasticity.
Tu B; Jiao Y; Herzog H; Nadler JV
Neuroscience; 2006 Dec; 143(4):1085-94. PubMed ID: 17027162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
